Niederer Kraft Frey advised SOPHiA Genetics SA (NASDQ: SOPH) on its secured credit facility with Perceptive Advisors.

SOPHiA Genetics, the data-driven medicine software company, entered on 2 May 2024 into a five-year senior secured credit facility with Perceptive Advisors, LLC, a privately owned sponsor that invests in biotechnology and life sciences sectors in public equity markets across the globe, for up to USD 50,000,000 in debt financing.

Under the terms of the agreement, Perceptive Advisors has been issued warrants to purchase shares of SOPHiA Genetics’ stock.

SOPHiA Genetics is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of SOPHiA DDM™, a platform that analyses complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions.

The NKF team was led by Corporate/M&A partner Jacques Bonvin and M&A/Finance partner Philip Spoerlé, working with partner Andrea Wuerzner (M&A/Banking) and associate Selim Lötscher (M&A/Finance), as well as partner Markus Kronauer and senior associate Sven Kälin (both Tax).